

JÃ©rÃ©me Alexandre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10746209/publications.pdf>

Version: 2024-02-01

45
papers

6,666
citations

331670

21
h-index

233421

45
g-index

51
all docs

51
docs citations

51
times ranked

13011
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	1.4	5
2	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	3.7	3
3	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e362-e368.	1.9	7
4	Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Final complete resection and pathological response rates.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5557-5557.	1.6	1
5	Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1044-1054.	10.7	35
6	Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1998-2008.	6.4	9
7	Prevalence of drugâ€“drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	2.3	4
8	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	6.1	6
9	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 155-160.	1.9	13
10	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	2.8	32
11	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	2.8	12
12	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
13	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	3.7	5
14	Dimethyl fumarate, a twoâ€“edged drug: Current status and future directions. <i>Medicinal Research Reviews</i> , 2019, 39, 1923-1952.	10.5	98
15	Is there an Exposureâ€“Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	3.7	28
16	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22506-e22506.	1.6	0
17	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 98-107.	1.9	22
18	Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. <i>Oncotarget</i> , 2018, 9, 9088-9099.	1.8	29

#	ARTICLE	IF	CITATIONS
19	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 174-183.	2.8	50
20	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. <i>American Journal of the Medical Sciences</i> , 2018, 356, 404-407.	1.1	5
21	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. <i>Pharmacological Research</i> , 2018, 136, 56-61.	7.1	11
22	Association of clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) with poor prognosis: Results of the CATS database.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17007-e17007.	1.6	1
23	Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 529-539.	4.1	54
24	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e493-e495.	1.9	2
25	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 30-36.	2.8	35
26	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	2.3	12
27	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2801-2811.	4.3	54
28	The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5521-5521.	1.6	1
29	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16022-e16022.	1.6	0
30	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	3.3	19
31	Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2881-2887.	1.6	114
32	Angiotensin System Inhibitors in Renal Cell CarcinomaâLetter. <i>Clinical Cancer Research</i> , 2016, 22, 524-524.	7.0	2
33	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared DecisionâMaking. <i>Oncologist</i> , 2015, 20, e26.	3.7	9
34	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 457-464.	10.7	93
35	Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 663-673.	2.4	15
36	Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. <i>Journal of Clinical Investigation</i> , 2014, 124, 262-272.	8.2	59

#	ARTICLE	IF	CITATIONS
37	A new strategy to target regulatory T cells in solid tumors. <i>Oncolmmunology</i> , 2013, 2, e23338.	4.6	6
38	Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer. <i>Journal of Immunology</i> , 2012, 189, 5171-5177.	0.8	58
39	Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2284-2293.	4.1	168
40	Bystander effect of vinorelbine alters antitumor immune response. <i>International Journal of Cancer</i> , 2011, 129, 1511-1518.	5.1	12
41	Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 579-591.	46.4	4,327
42	Novel Action of Paclitaxel against Cancer Cells: Bystander Effect Mediated by Reactive Oxygen Species. <i>Cancer Research</i> , 2007, 67, 3512-3517.	0.9	338
43	Improvement of the Therapeutic Index of Anticancer Drugs by the Superoxide Dismutase Mimic Mangafodipir. <i>Journal of the National Cancer Institute</i> , 2006, 98, 236-244.	6.3	172
44	Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2006, 119, 41-48.	5.1	284
45	Controlling tumor growth by modulating endogenous production of reactive oxygen species. <i>Cancer Research</i> , 2005, 65, 948-56.	0.9	364